HIMS vs TDOC: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
HIMS is the larger of the two ($4.52B market cap): the incumbent the market prices for continued execution (39.14x forward earnings). TDOC is the smaller challenger ($1.58B), priced similarly on forward earnings (-15.60x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
HIMS vs TDOC: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HIMS | TDOC | What it tells you |
|---|---|---|---|
| Market cap | $4.52B | $1.58B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 39.14 | -15.60 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Price vs 52-week range | 20% of range | 77% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.78 | 1.22 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how HIMS and TDOC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HIMS and TDOC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HIMS and TDOC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Hims & Hers Health (HIMS) do?
Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products on a subscription basis. Its categories span sexual health, hair loss and dermatology, mental health, and weight management, and the model is built on recurring monthly revenue: most customers are subscribers who refill automatically, which is why the company reports subscriber counts and revenue per subscriber as core metrics. It earns money primarily through these subscriptions and increasingly through higher-priced specialty offerings, and it has invested in owning more of its supply chain, including affiliated pharmacies and a lab and peptide facility.
What does Teladoc Health (TDOC) do?
Teladoc Health makes money through two reporting segments. Integrated Care sells virtual-care services (general medical, chronic-condition management for diabetes and hypertension via the former Livongo programs, expert medical opinions, and licensable platform tools) mostly to employers, health plans, and hospitals on a per-member-per-month and visit-fee basis; in 2025 it was the larger and more profitable engine, with Q2 2026 revenue of about $394 million and a 16.5% adjusted EBITDA margin. BetterHelp is a direct-to-consumer online mental-health and therapy subscription brand whose paying-member count and revenue have been falling; BetterHelp revenue declined about ~9% to roughly ~$950 million in 2025 and its segment adjusted EBITDA fell about ~46% to roughly ~$42 million as marketing costs rose, prompting a pivot toward insurance-reimbursed therapy.
HIMS vs TDOC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- HIMS drivers: Recurring subscription model; Category expansion beyond the original niche.
- TDOC drivers: Integrated Care and chronic-condition management; Free cash flow and balance-sheet discipline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026 and about 64 percent (adjusted) in the second quarter. For TDOC, revenue has been roughly flat to declining for several years, and total revenue fell about 2% in 2025 and about 4% in Q2 2026, so the turnaround is about stabilization rather than growth.
HIMS or TDOC: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HIMS if you believe its drivers more; TDOC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HIMS and TDOC guides.
HIMS vs TDOC: the full fundamentals
HIMS. With trailing net income negative, the trailing P/E is not meaningful, and at about $6.8 billion (as of October 2026) the market values Hims at roughly 2.6 times trailing sales and about 40 times forward earnings estimates. Analysts expect a loss of about $0.56 per share for 2026 and a return to profit (~$0.42) in 2027 on ~$4 billion of revenue. The valuation therefore rests on whether margins recover once the Eucalyptus integration, branded GLP-1 mix shift and FTC case are behind the company.
TDOC. As of October 16, 2026, Teladoc trades at about 0.4 times trailing sales and below book value, a valuation that prices in continued revenue decline rather than a turnaround. With GAAP losses ongoing, adjusted EBITDA and free cash flow remain the practical yardsticks, and the $130 to $170 million free cash flow guide equals a large share of the roughly $1.1 billion market cap. Analysts rate it hold on average, with a mean target near $7.59 across 17 firms.
Headline figures (approximate, October 2026): HIMS shows revenue (ttm) ~$2.58 billion, q2 2026 revenue ~$753 million (+38% YoY), q2 2026 eps -$0.37 vs ~-$0.05 estimate, net income (ttm) ~-$142 million; TDOC shows revenue (ttm) ~$2.49 billion; Q2 2026 revenue $606.9 million, down ~4% YoY, segment mix (q2 2026) Integrated Care $394.3 million (+1%); BetterHelp $212.6 million (-12%), adjusted ebitda Q2 2026 $65.7 million; FY2026 guidance $271 to $303 million, net income (ttm) ~-$177 million (GAAP loss); Q2 2026 EPS -$0.21 vs ~-$0.22 expected.
The bottom line: HIMS vs TDOC
HIMS and TDOC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HIMS and TDOC exposure against your real portfolio. It is not an investment adviser.
Wondering how HIMS or TDOC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Hims & Hers Health
Ask Walnut's AI anything about HIMS and see how it fits what you own.
FAQ
What is the difference between HIMS and TDOC?
+
Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products on a subscription basis. Teladoc Health makes money through two reporting segments. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HIMS or TDOC the better stock?
+
Neither is universally better. HIMS is the larger incumbent; TDOC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HIMS or TDOC?
+
On forward P/E (as of November 2026), HIMS trades at 39.14x and TDOC at -15.60x, so TDOC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HIMS and TDOC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HIMS vs TDOC?
+
HIMS: The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026 and about 64 percent (adjusted) in the second quarter. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 before acquisitions and branded GLP-1 sales lifted it to ~38 percent in the second quarter, but the company swung to GAAP losses in both quarters, so profitability rather than growth is now the main question. The FTC complaint filed July 29, 2026 and a related securities class action add legal risk, Eucalyptus integration and foreign expansion add execution risk, and the stock has historically fallen much harder than the market in sell-offs. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend. TDOC: Revenue has been roughly flat to declining for several years, and total revenue fell about 2% in 2025 and about 4% in Q2 2026, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of $38.9 million in Q2 2026 and about $177 million over the trailing twelve months) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care. The July 2026 cut to the BetterHelp outlook shows the cash-pay decline can run faster than planned, and the shares lost about 40% in the three months that followed.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HIMS or TDOC; figures are approximate and dated (as of November 2026). Verify current data before investing.